[go: up one dir, main page]

WO2000069914A3 - Humanized antibodies specific for egp-2 - Google Patents

Humanized antibodies specific for egp-2 Download PDF

Info

Publication number
WO2000069914A3
WO2000069914A3 PCT/GB2000/001910 GB0001910W WO0069914A3 WO 2000069914 A3 WO2000069914 A3 WO 2000069914A3 GB 0001910 W GB0001910 W GB 0001910W WO 0069914 A3 WO0069914 A3 WO 0069914A3
Authority
WO
WIPO (PCT)
Prior art keywords
egp
antibodies
humanized antibodies
antibodies specific
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/001910
Other languages
French (fr)
Other versions
WO2000069914A2 (en
Inventor
Hendricus Renerus J Hoogenboom
Anneke Reurs
Sigrid Herma Wilma Bei Beiboer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to AU49350/00A priority Critical patent/AU4935000A/en
Publication of WO2000069914A2 publication Critical patent/WO2000069914A2/en
Publication of WO2000069914A3 publication Critical patent/WO2000069914A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Human antibodies that recognize the epithelial glycoprotein antigen (EGP-2) are disclosed. The antibodies have a human light chain variable region and a human heavy chain variable region. Fragments of the antibodies and pharmaceutical compositions comprising the antibodies and their in vitro and in vivo applications in diagnosis and immunotherapy are also disclosed.
PCT/GB2000/001910 1999-05-18 2000-05-18 Humanized antibodies specific for egp-2 Ceased WO2000069914A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49350/00A AU4935000A (en) 1999-05-18 2000-05-18 Antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9911569.3 1999-05-18
GBGB9911569.3A GB9911569D0 (en) 1999-05-18 1999-05-18 Antibodies

Publications (2)

Publication Number Publication Date
WO2000069914A2 WO2000069914A2 (en) 2000-11-23
WO2000069914A3 true WO2000069914A3 (en) 2001-04-05

Family

ID=10853691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001910 Ceased WO2000069914A2 (en) 1999-05-18 2000-05-18 Humanized antibodies specific for egp-2

Country Status (3)

Country Link
AU (1) AU4935000A (en)
GB (1) GB9911569D0 (en)
WO (1) WO2000069914A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025565A2 (en) * 2001-09-21 2003-03-27 Caprion Pharmaceuticals Inc. Preparation of highly-purified plasma membranes
AU2002337885B1 (en) 2001-10-16 2003-04-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
HUE054986T2 (en) 2002-03-01 2021-10-28 Immunomedics Inc Immunoconjugate comprising humanised rs7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (en) 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
ES2526219T3 (en) 2003-04-30 2015-01-08 Universität Zürich Cancer treatment procedures using an immunotoxin
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
ES2531537T3 (en) * 2005-03-25 2015-03-17 National Research Council Of Canada Method for isolation of soluble polypeptides
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
KR20160055269A (en) 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
RU2016116549A (en) 2013-10-02 2017-11-09 Вивентиа Био Инк. ANTIBODIES AGAINST EPCAM AND WAYS OF THEIR APPLICATION
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
KR20220126813A (en) 2014-03-14 2022-09-16 노파르티스 아게 Antibody molecules against LAG-3 and uses thereof
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
KR102709593B1 (en) 2014-11-05 2024-09-26 제넨테크, 인크. Methods of producing two chain proteins in bacteria
AU2016228755B2 (en) 2015-03-12 2020-09-10 Viventia Bio Inc. Methods of treatment for EPCAM positive bladder cancer
HK1249731A1 (en) 2015-03-12 2018-11-09 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
AU2018275209A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
JP2020522691A (en) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Treatment of LAG-3-positive tumors
WO2020212914A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
CN110194803B (en) * 2019-06-26 2021-01-05 上海科棋药业科技有限公司 EpCAM-targeted chimeric antigen receptor and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEIBOER S H ET AL: "Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.", JOURNAL OF MOLECULAR BIOLOGY, (2000 FEB 25) 296 (3) 833-49., XP000944326 *
GRAVES S S ET AL: "Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody.", CLINICAL CANCER RESEARCH, (1999 APR) 5 (4) 899-908., XP000941615 *
HULS G A ET AL: "A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.", NATURE BIOTECHNOLOGY, (1999 MAR) 17 (3) 276-81., XP002141138 *
JESPERS L S ET AL: "Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen.", BIO/TECHNOLOGY, (1994 SEP) 12 (9) 899-903., XP002155177 *
ROOVERS R C ET AL: "High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein - 2 for tumour targeting.", BRITISH JOURNAL OF CANCER, (1998 DEC) 78 (11) 1407-16., XP000944264 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells

Also Published As

Publication number Publication date
GB9911569D0 (en) 1999-07-21
AU4935000A (en) 2000-12-05
WO2000069914A2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
WO2000069914A3 (en) Humanized antibodies specific for egp-2
WO1997019111A3 (en) Monoclonal antibodies anti-cd6 and their uses
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2003048321A3 (en) Hybrid antibodies
EP2325205A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002044217A3 (en) Humanised antibodies and uses thereof
DK0586002T3 (en) Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
HUP9802212A2 (en) Recombinant anti-cd4 antibodies for human therapy
EP2172476A3 (en) Compositions and methods for WT1 specific immunotherapy
BR0209177A (en) Recombinant tumor specific antibody and use
PL354508A1 (en) Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
HK1048477A1 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
PT1575484E (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2001005425A3 (en) Combined preparations comprising daunorubicin derivatives and her2 antibodies
WO2001036487A3 (en) Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
ATE208630T1 (en) IMMUNOTHERAPY MEDICINAL PRODUCTS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE THE MHCII ANTIGEN OF A PATIENT TO BE TREATED
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
WO2009015908A3 (en) Anti ephb4 antibodies and antibody fragments
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU5441000A (en) Human monoclonal antibody
ATE325803T1 (en) GLYCOCONJUGATES, GLYCOAMINO ACIDS, THEIR INTERMEDIATE PRODUCTS, AND THEIR USE
WO2003059260A3 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
ATE520704T1 (en) PEPTIDES FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED CANCER AND OTHER EPITHELIAL TUMORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP